Skip Navigation
Menu
ACP Journal Club |17 February 2009

Telmisartan did not reduce a composite of CV death, MI, HF, or stroke in high-risk patients intolerant to ACE inhibitors

Robin J. Taylor, MD

Article, Author, and Disclosure Information
FULL TEXT
Yusuf S for the TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-83. 18757085

Cardiology:

Most patients with CV disease or high-risk diabetes but preserved left ventricular function are given ACE inhibitors, based on the HOPE study, which showed reduction in CV morbidity and mortality (1). The ONTARGET trial found that telmisartan was noninferior in the minority of patients who were intolerant to ACE inhibitors, primarily because of cough (2).
It is thus surprising that TRANSCEND did not find telmisartan to be...
FULL TEXT
PDF
Not Available
Citations
Citation

Taylor RJ. Telmisartan did not reduce a composite of CV death, MI, HF, or stroke in high-risk patients intolerant to ACE inhibitors. Ann Intern Med. 2009;150:JC2–6. doi: https://doi.org/10.7326/0003-4819-150-4-200902170-02006

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2009;150(4):JC2-6.

DOI: 10.7326/0003-4819-150-4-200902170-02006

0 Citations

Related Articles
Telmisartan did not prevent recurrent stroke or major cardiovascular events
Annals of Internal Medicine; 150 (4): JC2-9
What kind of randomized trials do patients and clinicians need?
Annals of Internal Medicine; 150 (10): JC5-2
Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review
Annals of Internal Medicine; 169 (11): 774-787
Review: Folic acid may reduce risk for CVD and stroke, and B-vitamin complex may reduce risk for stroke
Annals of Internal Medicine; 169 (8): JC44
View MoreView Less

Journal Club
Telmisartan did not prevent recurrent stroke or major cardiovascular events
Annals of Internal Medicine; 150 (4): JC2-9
What kind of randomized trials do patients and clinicians need?
Annals of Internal Medicine; 150 (10): JC5-2
Review: Folic acid may reduce risk for CVD and stroke, and B-vitamin complex may reduce risk for stroke
Annals of Internal Medicine; 169 (8): JC44
In severe aortic stenosis with intermediate surgical risk, TAVR was noninferior to SAVR for death or disabling stroke
Annals of Internal Medicine; 166 (12): JC68
View MoreView Less

Related Point of Care
Transient Ischemic Attack
Annals of Internal Medicine; 154 (1): ITC1-1
View MoreView Less

Related Topics
Cardiology
Coronary Risk Factors
Hypertension
Nephrology
Neurology

Cardiology, Coronary Risk Factors, Hypertension, Nephrology, Neurology.

PubMed Articles
Gallstone Disease is an Independent Predictor for Poststroke Cognitive Impairment in Young Patients with Acute Ischemic Stroke.
Eur Neurol 2019.
Longzhibu disease and its therapeutic effects by traditional Tibetan medicine: Ershi-wei Chenxiang pills.
J Ethnopharmacol 2019.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×